Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01298843 · ClinicalTrials.gov registry record · Phase 4

Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital

A Phase 4 study of Infections, sponsored by Forest Laboratories.

Completed
Registry status
Phase 4
Development phase
53
Enrollment target
15
Study locations

NCT01298843: Completed Phase 4 study of Infections, sponsored by Forest Laboratories.

NCT01298843 is a Phase 4 study of Infections that has completed, run by Forest Laboratories. The registered enrollment target is 53 participants, below the 3,405-participant average among 26 other Infections trials with a reported enrollment target (98% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01298843, a Phase 4 study of Infections, has completed, sponsored by Forest Laboratories.

COMPLETED
Registry status
Phase 4
Development phase
53 participants
Enrollment target
15
Study locations

Study Summary

The purpose of this study is to assess blood levels of Ceftaroline fosamil in children.

Primary Outcome

This study has 3 primary outcome measures: plasma concentration of ceftaroline fosamil and its metabolites from blood samples after a single dose; PK profile of ceftaroline, and safety, where number of subjects with serious and non-serious adverse events and type of frequency of adverse events will be reported.

Conditions Studied

Interventions

  • DRUG Ceftaroline fosamil

Study Locations (15)

Ohio

  • Investigational Site - Akron
  • Investigational Site - Cleveland
  • Investigational Site - Cleveland
  • Investigational site - Toledo

California

  • Investigational Site - Orange
  • Investigational Site - San Diego

Arizona

  • Investigational Site - Phoenix

Arkansas

  • Investigational Site - Little Rock

Indiana

  • Investigational Site - Indianapolis

Kentucky

  • Investigational Site - Louisville

Louisiana

  • Investigational Site - Shreveport

Mississippi

  • Investigational Site - Jackson

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2011-04
Est. Completion 2013-02
Phase Phase 4
Forest Laboratories

145 total trials

What the finished NCT01298843 record still lists

NCT01298843 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 3,405-participant average among 26 other Infections trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Infections appearing as the primary indexed condition, and to 1 intervention - of which Ceftaroline fosamil is the first listed.

NCT01298843 lists 15 locations in 11 states (Ohio, California, Arizona).

Frequently Asked Questions

What is clinical trial NCT01298843 about?

NCT01298843 is a clinical study titled "Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital". The purpose of this study is to assess blood levels of Ceftaroline fosamil in children.

What is the current status of trial NCT01298843?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 53 participants. The study started on 2011-04. Estimated completion is 2013-02.

What conditions does trial NCT01298843 study?

This clinical trial studies the following conditions: Infections.

What interventions are being tested in trial NCT01298843?

The interventions under investigation include: Ceftaroline fosamil (DRUG).

Who is sponsoring clinical trial NCT01298843?

This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01298843 being conducted?

This trial has 15 study locations across Arizona, Arkansas, California, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01298843's enrollment target sits among peer trials

53 19th of 26 higher than 8 of 26 other Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04177004 · 53 participants · Phase 1

    Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

  • NCT04199741 · 53 participants · Phase 1

    PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

  • NCT04835129 · 53 participants · Phase 2

    Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

  • NCT04913805 · 53 participants · Phase 2

    Matching Perfusion and Metabolic Activity in HFpEF

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01298843, the US trial registry maintained by the National Library of Medicine. NCT01298843 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.